Alzheimer’s disease could be slowed by boosting a certain protein in the brain, researchers say
Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The University of Cincinnati researchers and an Alzheimer's Association expert weigh in.
Study shows Alzheimer’s drugs may boost protein, not just lower amyloid
Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, the drugs boost levels of a healthy form of amyloid beta (Aβ42) protein in the brain,
Boosting brain protein levels may slow decline from Alzheimer's
A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the slowing of cognitive impairment at least as well as the reduction in amyloid plaques.
Alzheimer's Decline May Be Slowed by Protein Boost
"Aβ42 is a protein that defends our brain from a variety of toxic and infectious exposures," Espay said. "In the process of reacting, it transforms into amyloid plaques. Amyloid plaques is made of clumped up Aβ42. Once in amyloid, Aβ42 no longer works (the plaques can be viewed as a tombstone of Aβ42)."
Alzheimer's Drugs May Work in Whole New Way, Study Finds
Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years. It's thought the drugs curb Alzheimer's by reducing levels of toxic amyloid protein plaques in the brain.
Boosting brain protein levels may slow Alzheimer’s progression
A new study published in the journal Brain reveals that increasing levels of a key brain protein might help slow cognitive decline in Alzheimer’s patients. This finding challenges the long-held belief that reducing amyloid plaques is the best way to treat the disease.
Study finds Alzheimer's drugs might boost healthy protein in brain
Researchers have discovered that Alzheimer's drugs Leqembi and Kisunla boost levels of a healthy form of protein in the brain, even as they reduce its more toxic form.
Medical News Today1d
New study challenges amyloid-beta theory on cause for Alzheimer's disease
New research suggests that the lessening of amyloid-beta in the brain is behind cognitive decline in Alzheimer's and boosting ...
Amyloid Plaques May Not Cause Alzheimer’s: New Research Challenges Decades-Old Theories
A study shows that rising levels of brain protein Aβ42, not the reduction of amyloid plaques, better explains the cognitive ...
ALZFORUM7y
Alzheimer's Disease vs Control: Aβ42 (Plasma and Serum)
However, while the level of Aβ42 in blood is not by itself a good biomarker for AD, the Aβ42:Aβ40 ratio has gained attention as a plasma biomarker that predicts amyloid-PET status regardless of ...
Endocrinology Advisor6d
Caffeine Intake Might Protect Against Alzheimer Disease, Mild Cognitive Impairment
Caffeine and Alzheimer disease risk appear to be linked, as lower caffeine intake is associated with Alzheimer disease biomarkers.
precisionmedicineonline6d
NKGen Biotech Doses First Patient in Phase II Portion of Alzheimer's Cell Therapy Trial
Three months after treatment with troculeucel, two patients in the Phase I portion went from having moderate to mild symptoms of dementia.
ALZFORUM3y
Progressive Supranuclear Palsy vs Alzheimer's Disease: Aβ42 (Plasma and Serum)
Meta-analysis of two studies showed that levels of Aβ42 in plasma were slighlty higher in people with progressive supranuclear palsy than people with Alzheimer's disease (effect size = 1.16).